Eichholz, Thomas
Heubach, Florian
Arendt, Anne-Marie
Seitz, Christian
Brecht, Ines B.
Ebinger, Martin
Flaadt, Tim
Süsskind, Daniela
Richter, Lisa
Hülsenbeck, Isabel
Zerweck, Leonie
Göricke, Sophia
Paulsen, Frank
Dombrowski, Frank
Flotho, Christian
Schönberger, Stefan
Ketteler, Petra
Schulte, Johannes
Lang, Peter
Funding for this research was provided by:
excellence cluster iFIT (EXC 2180) [Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) im Rahmen der Exzellenzstrategie des Bundes und der Länder] (WXC 2180 – 390900677)
German Cancer Consortium
Dieter Schwarz Stiftung Neckarsulm
Foerderverein and the Stiftung fuer krebskranke Kinder Tuebingen e.V.
Universitätsklinikum Tübingen
Article History
Received: 18 July 2023
Accepted: 10 December 2023
First Online: 19 January 2024
Declarations
:
: Financial interests: T.F. has received research funding and travel expenses from Eusapharma. Non-financial interests: P.K. and T.F. are members of the advisory board of Eusapharma.
: Informed consent to participate the RB-registry was obtained from the legal representatives. The treatment centers obtained informed consent from the legal representatives in the individual off-label treatment attempt with Db.
: Approval of RB-registry was granted by the ethical committee, University of Duisburg-Essen (approval number 13-5405-BO). The study was performed in line with the principles of the declaration of Helsinki.